A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2015 by Millennium Pharmaceuticals, Inc.
Seattle Genetics, Inc.
Information provided by (Responsible Party):
Millennium Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
First received: March 27, 2012
Last updated: February 23, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: June 2015
  Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)